REFERENCES
1. Prader A, Labhart A, Willi H. Ein syndrom von adipositas, kleinwuchs, kryptorchismus und oligophrenie nach myatonieartigem zustand im neugeborenenalter. Schweiz Med Wochenschr. 1956;86:1260-1. Available from: https://www.scienceopen.com/document?vid=a8320db5-9d18-41e2-8d53-491fc0e120ae [Last accessed on 3 Jun 2025].
2. Tauber M, Hoybye C. Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol. 2021;9:235-46.
3. Eiholzer U, Gisin R, Weinmann C, et al. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr. 1998;157:368-77.
4. Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab. 2010;95:1131-6.
5. Bakker NE, Kuppens RJ, Siemensma EPC, et al. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab. 2013;98:4013-22.
6. von Mil EG, Westerterp KR, Gerver WJ, Van Marken Lichtenbelt WD, Kester AD, Saris WH. Body composition in Prader-Willi syndrome compared with nonsyndromal obesity: relationship to physical activity and growth hormone function. J Pediatr. 2001;139:708-14.
7. Boot AM, de Ridder MA, van der Sluis IM, van Slobbe I, Krenning EP, Keizer-Schrama SM. Peak bone mineral density, lean body mass and fractures. Bone. 2010;46:336-41.
8. Gordon CM, Zemel BS, Wren TA, et al. The determinants of peak bone mass. J Pediatr. 2017;180:261-9.
9. Angulo MA, Castro-Magana M, Lamerson M, Arguello R, Accacha S, Khan A. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet A. 2007;143A:1456-61.
10. Lindgren AC, Lindberg A. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database). Horm Res. 2008;70:182-7.
11. Griffing E, Halpin K, Lee BR, Paprocki E. Premature pubarche in Prader-Willi syndrome: risk factors and consequences. Clin Endocrinol. 2024;101:162-9.
12. Gaston LS, Stafford DE. Premature adrenarche in Prader-Willi syndrome is associated with accelerated pre-pubertal growth and advanced bone age. J Pediatr Endocrinol Metab. 2023;36:185-94.
13. Prader A, Largo RH, Molinari L, Issler C. Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta Suppl. 1989;52:1-125.
14. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. University Press; 1959, p. 256.
15. Ofenheimer A, Breyer-Kohansal R, Hartl S, et al. Reference charts for body composition parameters by dual-energy X-ray absorptiometry in European children and adolescents aged 6 to 18 years-Results from the Austrian LEAD (Lung, hEart, sociAl, boDy) cohort. Pediatr Obes. 2021;16:e12695.
16. R Core Team. The R project for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available from: https://www.R-project.org/ [Last accessed on 3 Jun 2025].
17. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Soft. 2015;67:1-48.
18. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Soft. 2017;82:1-26.
19. Gamage DS, Ambler G, Chan A, Srinivasan S, Maguire AM, Cho YH. Outcomes of growth hormone treatment in children with Prader-Willi syndrome over a 30-year period: a single tertiary center experience. J Pediatr Endocrinol Metab. 2024;37:680-5.
20. Noordam C, Höybye C, Eiholzer U. Prader-Willi Syndrome and hypogonadism: a review article. Int J Mol Sci. 2021;22:2705.
21. Schmidt H, Schwarz HP. Premature adrenarche, increased growth velocity and accelerated bone age in male patients with Prader-Labhart-Willi syndrome. Eur J Pediatr. 2001;160:69-70.
22. L'Allemand D, Eiholzer U, Rousson V, et al. Increased adrenal androgen levels in patients with Prader-Willi syndrome are associated with insulin, IGF-I, and leptin, but not with measures of obesity. Horm Res. 2002;58:215-22.
23. Siemensma EP, de Lind van Wijngaarden RF, Otten BJ, de Jong FH, Hokken-Koelega AC. Pubarche and serum dehydroepiandrosterone sulphate levels in children with Prader-Willi syndrome. Clin Endocrinol. 2011;75:83-9.
24. Lecka-Ambroziak A, Wysocka-Mincewicz M, Marszałek-Dziuba K, Rudzka-Kocjan A, Szalecki M. Premature adrenarche in children with Prader-Willi syndrome treated with recombinant human growth hormone seems to not influence the course of central puberty and the efficacy and safety of the therapy. Life. 2020;10:237.
25. Brambilla P, Bosio L, Manzoni P, Pietrobelli A, Beccaria L, Chiumello G. Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr. 1997;65:1369-74.
26. Goldstone AP, Brynes AE, Thomas EL, et al. Resting metabolic rate, plasma leptin concentrations, leptin receptor expression, and adipose tissue measured by whole-body magnetic resonance imaging in women with Prader-Willi syndrome. Am J Clin Nutr. 2002;75:468-75.
27. Theodoro MF, Talebizadeh Z, Butler MG. Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity. Obesity. 2006;14:1685-90.
28. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab. 2002;87:1581-5.
29. Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr. 2000;137:42-9.
30. Grootjen LN, Trueba-Timmermans DJ, Damen L, Mahabier EF, Kerkhof GF, Hokken-Koelega ACS. Long-term growth hormone treatment of children with PWS: the earlier the start, the better the outcomes? J Clin Med. 2022;11:2496.
31. Plotkin LI, Bruzzaniti A, Pianeta R. Sexual dimorphism in the musculoskeletal system: sex hormones and beyond. J Endocr Soc. 2024;8:bvae153.
32. Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15:321-35.
33. Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ. Obesity paradox in cardiovascular disease: where do we stand? Vasc Health Risk Manag. 2019;15:89-100.
34. Eiholzer U, Stephan A, Fritz C, Katschnig C, Noordam C; Clinical and Scientific Advisory Board of the International Prader-Willi Syndrome Organisation (IPWSO). Gonadal hormone substitution in people with Prader-Labhart-Willi Syndrome: an international Prader-Willi Syndrome organisation survey. Horm Res Paediatr. 2021;94:176-85.
35. Eiholzer U, Nordmann Y, L'Allemand D, Schlumpf M, Schmid S, Kromeyer-Hauschild K. Improving body composition and physical activity in Prader-Willi Syndrome. J Pediatr. 2003;142:73-8.
36. Diene G, Angulo M, Hale PM, et al. Liraglutide for weight management in children and adolescents with Prader-Willi syndrome and obesity. J Clin Endocrinol Metab. 2022;108:4-12.
37. Ng NBH, Low YW, Rajgor DD, et al. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: a systematic review. Clin Endocrinol. 2022;96:144-54.
38. Eiholzer U, Whitman BY. A comprehensive team approach to the management of patients with Prader-Willi syndrome. J Pediatr Endocrinol Metab. 2004;17:1153-75.
39. Hirsch HJ, Benarroch F, Genstil L, et al. Long-term weight control in adults with Prader-Willi syndrome living in residential hostels. Am J Med Genet A. 2021;185:1175-81.
